0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules

RICHARD J. GRALLA, M.D.; EPHRAIM S. CASPER, M.D.; DAVID P. KELSEN, M.D.; DAVID W. BRAUN Jr., Ph.D.; MARY E. DUKEMAN; NAEL MARTINI, M.D.; CHARLES W. YOUNG, M.D.; and ROBERT B. GOLBEY, M.D.
[+] Article and Author Information

Grant support: in part by contract NO-1CM57043 and grant CA-05826, National Institutes of Health. Drs. Gralla and Casper are recipients of the American Cancer Society Junior Faculty Fellowship Awards, and Dr. Kelsen is the recipient of a Landrum/Karnofsky Scholarship.

Published in part in abstract form in Proc Am Soc Clin Oncol. 1979:20;337; and in: HANSEN HH, DOMBERNOWSKY P, eds. Abstracts of the Second World Conference on Lung Cancer. Amsterdam: Exerpta Medica; 1980:229.

▸Requests for reprints should be addressed to Richard J. Gralla, M.D.; Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue; New York, NY 10021.


New York, New York


© 1981 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1981;95(4):414-420. doi:10.7326/0003-4819-95-4-414
Text Size: A A A

Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with either high dose (120 mg/m2 of body surface area) or low dose (60 mg/m2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43% complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 versus 5.5 months; p = 0.05) and in median survival for responding patients (21.7 versus 10 months; p = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)